You are here

  • Home
  • Archive
  • Volume 3, Issue 1
  • Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

Article metrics

Article menu

Download PDFPDF

Research Article
Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

 

Online download statistics by month:

Online download statistics by month: December 2019 to August 2024

AbstractFullPdf
Dec 2019220
Jan 2020550
Feb 202014142
Mar 202011111
Apr 202018182
May 202023233
Jun 202011111
Jul 202015154
Aug 2020773
Sep 202024245
Oct 202027277
Nov 202014146
Dec 202011114
Jan 202113132
Feb 2021882
Mar 202113130
Apr 202113133
May 202117175
Jun 202118180
Jul 202123230
Aug 202119196
Sep 202136369
Oct 202128284
Nov 202120203
Dec 202129308
Jan 202254562
Feb 202234373
Mar 202229293
Apr 202229308
May 202237415
Jun 202243432
Jul 202226317
Aug 202238388
Sep 2022292915
Oct 202232357
Nov 2022404213
Dec 202248495
Jan 202351529
Feb 202352534
Mar 202330312
Apr 202328297
May 202327277
Jun 202337397
Jul 2023292910
Aug 202317185
Sep 202372725
Oct 20231131138
Nov 202382825
Dec 202356566
Jan 202498996
Feb 2024697010
Mar 2024202032
Apr 202415715738
May 2024515211
Jun 2024282810
Jul 202448517
Aug 2024444255
Total19672000402